Viewing Study NCT06355037



Ignite Creation Date: 2024-05-06 @ 8:21 PM
Last Modification Date: 2024-10-26 @ 3:26 PM
Study NCT ID: NCT06355037
Status: RECRUITING
Last Update Posted: 2024-07-08
First Post: 2024-03-30

Brief Title: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Sponsor: Fudan University
Organization: Fudan University

Study Overview

Official Title: a Pilot Study to Explore the Efficacy and Safety of Dasatinib Combined With Quercetin to Reverse Chemotherapy Resistance in Triple Negative Breast Cancer
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a Phase II open-label single-arm study evaluating the efficacy and safety of combined treatment of dasatinib quercetin with chemotherapy in mTNBC triple negative breast cancer patients who progressed during previous chemotherapy
Detailed Description: This is a Phase II open-label single-arm study evaluating the efficacy and safety of combined treatment of dasatinib quercetin with chemotherapy in mTNBC triple negative breast cancer patients who progressed during previous chemotherapy Chemotherapy is the backbone drug for TNBC How to reverse chemotherapy resistance or how to increase the sensitivity of chemotherapy efficacy has become an urgent clinical problem to be solved Our preclinical studies have demonstrated that the combination of dasatinib and quercetin with chemotherapy can effectively eliminate chemotherapy-induced senescent fibroblasts decrease the proliferation rate of disseminated tumor cells and ultimately lead to a significant reduction in metastasis and recurrence thereby enhancing the efficacy of chemotherapy Based on preclinical studies the investigators designed this study to enroll mTNBC patients who have progressed during or following chemotherapy and to explore the efficacy of combined treatment of dasatinib quercetin with chemotherapy at a clinical level providing new strategies of combined treatment for TNBC patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None